Gilead Sciences Stops Patient Enrollment In BIRCH Study Evaluating Obeldesivir, Citing ' lower-than-expected COVID-19 incidence rates and related hospitalizations or all-cause death by Day 29'; Patients Already Enrolled Will Continue In Study
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has halted patient enrollment in its BIRCH study evaluating Obeldesivir due to lower-than-expected COVID-19 incidence rates and related hospitalizations or all-cause death by Day 29. However, patients already enrolled will continue in the study.
September 28, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead's decision to halt enrollment in the BIRCH study could potentially slow down the development and approval process of Obeldesivir, which may negatively impact the company's stock in the short term.
The halt in patient enrollment for the BIRCH study could delay the development and approval process of Obeldesivir. This could potentially lead to a delay in revenue generation from the drug, which may negatively impact Gilead's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100